In patients with unresectable metastatic melanoma, T-VEC demonstrated a superior durable response rate (continuous complete response or partial response lasting ≥ 6 months) over subcutaneous GM-CSF (16.3% vs. 2.1%; p < 0.001). The gene discussed is CSF2; the disease is metastatic melanoma.